Background
Diabetes mellitus is a metabolic disease, which is characterized by the hyperglycemia due to either insulin insufficiency or resistance. There are more than 90% cases with type 2 diabetes where the cells in the body show reduced reaction to insulin (insulin resistance). Diabetes is the seventh most common cause of death in the United States, and it causes a variety of health complications including heart disease, blindness, kidney failure, and lower-extremity amputations. Numerous pathogenic processes are implicated in the development of diabetes, which result from the β-cell destruction in the pancreas leading to insulin deficiency or from the abnormalities that cause insulin resistance in target tissues [
1,
2]. The abnormal inflammatory responses have been shown to play important roles in the pathogenesis and progression of type 2 diabetes [
3‐
5]. For instance, pro-inflammatory cytokines including interleukin (IL)-6 and tumor necrosis factor (TNF)-α enhance insulin resistance, and are associated with increased risk of type 2 diabetes [
6‐
9]. In contrast, IL-10, an anti-inflammatory cytokine, is reduced in patients with type 2 diabetes [
10]. Therefore, the therapeutic treatments with anti-inflammatory properties would be beneficial to the management of type 2 diabetes.
Metformin is the first-line therapy for the treatment of type 2 diabetes by repressing the hepatic gluconeogenesis [
11‐
13]. The molecular mechanism of metformin is associated with the activation of AMP-activated protein kinase (AMPK) and protein kinase A (PKA) as well as the inhibition of the mitochondrial respiratory chain (complex I) and glycerophosphate dehydrogenase. It has been suggested that metformin improves metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, thereby reducing chronic inflammatory responses [
14,
15]. However, it is not clear whether metformin has any effects on inflammatory responses in the systemic circulation and urine of patients with type 2 diabetes. In the present study, we determined the effects of metformin with different doses and durations on the levels of pro-inflammatory cytokines (i.e., IL-6, TNF-α, and MCP-1) and anti-inflammatory mediator IL-10 in blood and urine of patients with type 2 diabetes.
Methods
Patient enrollment
There were 210 patients diagnosed with type 2 diabetes during the period of January 2015 to December 2015 in the Anhui Provincial Hospital. The characteristics of these patients were shown in Table
1. The criteria for patient inclusion were shown as the following: 1) All patients are diagnosed according to the WHO diagnostic guidelines (1999 version) for type 2 diabetes; 2) ages are between 42 and 70; 3) 4.8% ≤ glycated hemoglobin A1c ≤ 7.5%. The criteria for patient exclusion were described as the following: 1) Patients with acute infection in past two months; 2) Any systemic immune disorders; 3) Chronic infectious diseases and tumors; 4) Surgical operation within last three months; 5) Severe hepatic and kidney dysfunction; and 6) Extremely high blood pressure.
Table 1
Changes in blood pressure, hepatic and renal biochemistry between metformin and non-metformin groups
Blood glucose (mmol/L) | 6.41 ± 0.98 | 112 | 6.33 ± 0.90 | 169 | 0.4993 |
Systolic blood pressure (mmHg) | 133.29 ± 11.24 | 112 | 134.63 ± 9.43 | 169 | 0.2718 |
Diastolic blood pressure (mmHg) | 73.69 ± 7.23 | 112 | 74.22 ± 6.78 | 169 | 0.5271 |
Hemoglobin A1c (%) | 6.40 ± 0.57 | 112 | 6.29 ± 0.60 | 169 | 0.1260 |
Body mass index | 25.66 ± 3.64 | 112 | 25.18 ± 3.43 | 169 | 0.2584 |
Total cholesterol (mmol/L) | 4.71 ± 1.26 | 112 | 4.61 ± 0.90 | 169 | 0.4265 |
Triglyceride (mmol/L) | 1.90 ± 1.27 | 112 | 1.58 ± 0.99 | 169 | 0.0205 |
HDL(mmol/L) | 1.13 ± 0.30 | 87 | 1.16 ± 0.32 | 59 | 0.5051 |
LDL (mmol/L) | 2.66 ± 0.82 | 112 | 2.76 ± 0.81 | 169 | 0.3443 |
VLDL (mmol/L) | 0.81 ± 0.41 | 87 | 0.69 ± 0.45 | 59 | 0.0988 |
Creatinine (μmol/L) | 83.02 ± 17.49 | 112 | 85.89 ± 32.90 | 169 | 0.3979 |
All these 210 patients with type 2 diabetes were randomly divided into metformin (n = 112) and non-metformin (n = 98) groups. For the metformin group, patients received metformin (1000 mg or 1500 mg) daily through oral administration. For the non-metformin group, patients received one of the following drugs: gliclazide (a sulfonylurea, n = 44), acarbose (a glucosidase inhibitor, n = 18), and repaglinide (stimulating the release of insulin, n = 36) for 12 months.
Measurement of cytokine by ELISA
Serum was obtained from patient venous blood through centrifugation for 10 min at 1500 rpm. Similarly, the urine was collected followed by the centrifugation, and kept at −80 °C until analysis. The levels of IL-6, IL-10 and TNF-α in serum and monocyte chemoattractant protein-1 (MCP-1) in urine were measured using the corresponding ELISA kits from R&D Systems (Minneapolis, MN, USA) according the manufacturer’s protocols.
Statistics
All statistical analysis was performed by the Graphpad Prism software, and the differences between two groups (e.g., metformin vs every treatment) were compared using a Dunnett’s post-hoc test following an ANOVA.
Discussion
In the present study, we found that metformin treatment has specific effects on cytokines (serum IL-6 and urinary MCP-1) as compared to the non-metformin (i.e., gliclazide, acarbose, or repaglinide) treatment type 2 diabetic patients. When compared to individual gliclazide, acarbose, or repaglinide treatment, metformin significantly reduced the pro-inflammatory cytokines in serum and urine. In addition, metformin reduced inflammatory responses in a duration- and dose-dependent manner in patients with type 2 diabetes. These findings suggest that metformin (1000 mg, q.d.) for 1 year has beneficial effects to reduce inflammatory responses in systemic circulation and urine in type 2 diabetic patients.
In addition to diet control and exercise, type 2 diabetic patients commonly require diabetes medications and insulin. The most commonly prescribed medication for type 2 diabetes is metformin with less side-effect of hypoglycemia. As compared to gliclazide, acarbose, or repaglinide, there were no significant changes in biochemical parameters for hepatic and renal function. These results suggest that the medications including metformin for type 2 diabetic patients in this study are safe.
A variety of mechanisms contribute to defective insulin secretion and responses in type 2 diabetes, which including glucotoxicity, lipotoxicity, oxidative stress, and the formation of amyloid deposits in the islets [
18,
19]. Interestingly, all of these mechanisms are associated with inflammatory responses [
20]. This is corroborated by the findings that chronic inflammatory responses play important roles in the pathogenesis of type 2 diabetes by causing islet dysfunction and insulin resistance in both inflammasome-dependent or -independent manners [
21]. Therefore, the ideal anti-diabetic drugs would be possessing anti-inflammatory properties in addition to reducing glucose in blood. In comparison with gliclazide, acarbose, and repaglinide, metformin reduced the levels of serum IL-6, TNF-α, and urinary MCP-1 in patients with type 2 diabetes. In addition, metformin exhibits a specific effect on inflammatory responses at the different doses and durations. Altogether, these findings suggest that metformin exhibits anti-diabetic effects by reducing both glucose levels and inflammatory responses.
It is well-known that metformin treatment in diabetic patients with chronic kidney diseases would be cautious, as it causes lactic acidosis in the setting of renal dysfunction [
22,
23]. In our study, we did not find any abnormalities of renal function in these diabetic patients treated with metformin or non-metformin. Future studies are required to determine how metformin reduces MCP-1 reduction in urine without changes in renal function. In addition, the disadvantage of this study is unable to determine the effects of metformin or other anti-diabetic drugs on inflammatory responses through a longitudinal manner.
Conclusion
Metformin reduces inflammatory responses in addition to glucose reduction in type 2 diabetic patients. There are specific effects on cytokines (serum IL-10 and urinary MCP-1) by the different durations and doses of metformin in patients with type 2 diabetes. Therefore, metformin reduces inflammatory responses in systemic circulation and urine, which contributes to its beneficial effects on type 2 diabetes.
Acknowledgements
No applicable
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.